Search for: "In re National Research Corporation shareholder litigation"
Results 81 - 87
of 87
Sorted by Relevance
|
Sort by Date
20 Jun 2008, 8:07 am
– Marks & Clerk Biotechnology Report 2008: (IP finance), Pfizer and Daiichi-Sankyo’s bidding for Ranbaxy: (IP ThinkTank), (IAM), (Managing Intellectual Property), (GenericsWeb), Cutting Edge Information study reveals 53% of pharma patents approach expiration before litigation strategies are implemented: (Peter Zura's 271 Patent Blog), Quanta and agricultural biotechnology: (Holman’s Biotech IP Blog), Breakthough by WHO will give poor countries… [read post]
3 Dec 2021, 9:49 am
That’s hard to explain to shareholders. . . . [read post]
3 Dec 2021, 9:49 am
That’s hard to explain to shareholders. . . . [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to dodge real… [read post]
14 Mar 2023, 3:42 pm
According to the National Research Council, TCDD, or what is often just called dioxin, “is among the most toxic anthropogenic substances ever identified” and has been implicated in various high-profile industrial disasters, such as Times Beach Missouri as well as the tragedy of Agent Orange. [read post]
2 Nov 2021, 8:49 am
President Alberto Fernández stated: “We’re making good on our word to put the country back on its feet and that the debt wasn’t going to impede us from achieving a process of development for our jobs and production”. [read post]
10 May 2023, 4:00 am
This book is written in a way that makes it useful for fast fact-checking and shows how to do deeper research. [read post]
